Endocrine Abstracts

Introduction: Polycystic ovary syndrome (PCOS) is the most common endocrine pathology in premenopausal women and it is a complex syndrome affecting various systems. Numerous studies have been made about how the PCOS effects on bone metabolism, but currently there is no clear information. Wnt pathway plays important role in the regulation of bone metabolism. The sclerostin(Scl) and Dickkopf-1 (DKK1) inhibit this pathway and they has recently become a therapeutic target of osteoporosis. In this study, we aimed to show the Scl and DKK1 levels in women with PCOS.

Methods: This study was conducted in Çanakkale Onsekiz Mart University Endocrinology department. Thirty-six women with PCOS and 35 healthy volunteers were examined in this study. Both groups were compared in terms of respect demographic, anthropometric, biochemical and Scl and DKK levels.

Results: PKOS grubunda sklerostin düzeyi 42.68±13.28 pg/ml, kontrol grubunda ise 45.69±11.79 pg/ml olarak ölçülmüş olup iki grup arasında istatistiki anlamlı fark olmadığı tespit edilmiştir. DKK1 düzeylerinin ise PKOS’lularda 1444.73±611.30 pg/ml, kontrol grubunda 1204.26±660.88 pg/ml olduğu gösterilmiş olup iki grup arasında anlamlı fark olmadığı saptanmıştır. The proportion of clinical hirsutism (FGS≥8) in PCOS group were significantly higher than the control group. PCOS group compared to the control group in BMI and WHR were found to be high, although the difference is not statistically significant.

Conclusions: This is the first study on this subject. Çalışmamızda PKOS’lu kadınlarda sklerostin ve DKK1 düzeylerinin değişmediği gösterilmiştir. PKOS’lu hastaların KMY ölçümleriyle olan çalışmalarda da çelişkili sonuçlar çıkmıştır. Her ne kadar amenore bu hastalarda kemik kaybına yol açıyorsa da, hiperandrojenemi ve hiperestrojenemi gibi durumlar kemik üzerine olumlu etkiler yaparak bu etkiyi dengeliyor görünmektedir.

Keywords: Polycystic Ovary Syndrome, Osteoprosis, Sclerostin, Dickkopf-1